Semaglutide vs Tirzepatide: Comparing the Heavyweights

For a few years, comparing semaglutide and tirzepatide meant lining up results from separate trials run in different populations, an apples-to-oranges exercise that invited overconfident conclusions. Now there is direct head-to-head evidence: SURMOUNT-5, published in The New England Journal of Medicine in 2025, randomized the two drugs against each other. That changes the quality of the comparison considerably. The short version: tirzepatide produced more weight loss, but the fuller picture involves mechanism, tolerability, and the realities of access and cost.

How do semaglutide and tirzepatide differ?

Semaglutide is a GLP-1 receptor agonist. It mimics the incretin hormone GLP-1 to enhance glucose-dependent insulin release, slow gastric emptying, and reduce appetite through action on the brain.

Tirzepatide is a dual agonist: it engages both the GLP-1 receptor and the GIP receptor. GIP is another incretin hormone, and the prevailing hypothesis is that hitting both pathways produces additive or complementary effects on appetite and metabolism. Whether GIP agonism is the whole explanation for tirzepatide’s larger effect is still being worked out, but the dual-target design is the structural difference between the two drugs. Carrots, vegetables, harvest — illustrating Semaglutide vs Tirzepatide: Comparing the Heavyweights

In SURMOUNT-5, tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide over 72 weeks. That’s a meaningful finding, but “greater on average” is not “better for every individual,” and the trade-offs deserve equal billing.

Is tirzepatide stronger than semaglutide?

Lime, 4k wallpaper, mac wallpaper — illustrating Semaglutide vs Tirzepatide: Comparing the Heavyweights

SURMOUNT-5 enrolled 751 adults with obesity (or overweight with comorbidities) and no diabetes, comparing tirzepatide (10 or 15 mg) against semaglutide (1.7 or 2.4 mg) over 72 weeks. The headline result: tirzepatide cut body weight by 20.2% on average versus 13.7% for semaglutide, roughly 22.8 kg versus 15.0 kg. Waist circumference fell more on tirzepatide too (−18.4 cm vs −13.0 cm). The difference is clinically meaningful, not trivial. Both, it’s worth stressing, deliver weight loss far beyond what earlier-generation agents achieved.

A balanced read of the comparison:

	Semaglutide	Tirzepatide
Mechanism	GLP-1 receptor agonist	Dual GLP-1 + GIP receptor agonist
Brands	Ozempic, Wegovy, Rybelsus	Mounjaro, Zepbound
Weight loss (SURMOUNT-5)	13.7% (15.0 kg)	20.2% (22.8 kg)
Waist circumference	−13.0 cm	−18.4 cm
GI discontinuation (SURMOUNT-5)	5.6%	2.7%
Cardiovascular outcomes	SELECT: 20% relative MACE reduction, 17,604 patients	Outcomes data still accumulating
Oral form	Yes (Rybelsus)	No

Beyond### Why would a doctor prescribe semaglutide instead?

Vegetables, fruits, food — illustrating Semaglutide vs Tirzepatide: Comparing the Heavyweights

Real-world choice isn’t decided by effect size alone. Cost, insurance coverage, supply availability, individual tolerability, and specific clinical history all weigh in. A person who tolerates one poorly may do far better on the other, and the “less effective on average” option can be the right one for a given individual.

It’s also worth naming the unknown: long-term comparative outcomes (durability of weight loss after stopping, and head-to-head cardiovascular and other hard endpoints over many years) are still accumulating.

The takeaway

The honest summary is narrower than the headlines. Direct head-to-head evidence (SURMOUNT-5) shows tirzepatide produces more weight loss on average (20.2% vs 13.7%), and that’s a real advantage. But semaglutide carries a deeper cardiovascular outcomes record, the two share a similar side-effect profile, and the best choice for an individual depends on tolerability, cost, access, and clinical context as much as on average efficacy. Both are powerful tools. Neither is a default for everyone, and decisions belong with a clinician who knows the specific case.

Frequently asked questions

Is tirzepatide stronger than semaglutide?

For weight loss, on average, yes. SURMOUNT-5 randomised 751 adults with obesity and no diabetes and found 20.2% average weight loss on tirzepatide against 13.7% on semaglutide over 72 weeks. “Stronger on average” is a statement about a trial population, not a prediction for any individual.

Do you lose more muscle on semaglutide or tirzepatide?

No head-to-head trial has published body-composition data comparing the two. SURMOUNT-5 reported total weight, not the lean-versus-fat split, so anyone claiming one preserves muscle better than the other is going beyond the evidence. What is established is that GLP-1 weight loss includes lean mass on both — see protecting lean mass on a GLP-1.

Why would a doctor prescribe semaglutide instead of tirzepatide?

Several reasons that have nothing to do with average efficacy. Semaglutide has the deeper cardiovascular outcomes record — SELECT enrolled 17,604 patients and showed a 20% relative reduction in major cardiac events. It is also the only one of the two with an oral form (Rybelsus). Insurance coverage, supply, and how a specific person tolerates each drug often decide the choice before effect size does.

What makes you less sick, semaglutide or tirzepatide?

Both share the class’s gastrointestinal side effects, concentrated during dose escalation. In SURMOUNT-5, GI events leading to discontinuation were somewhat more common on semaglutide (5.6%) than tirzepatide (2.7%) — a real difference, but a small one, and not a reliable guide to how any individual will tolerate either.

How long does it take to lose 20 lbs on tirzepatide?

The trial does not answer this directly, and any specific timeline would be invented. SURMOUNT-5 measured 20.2% average loss over 72 weeks, which for a 200 lb starting weight works out to roughly 40 lb across the full trial period. Individual rates varied widely, and loss is not linear — it is fastest during dose escalation and flattens later.